The shareholder Shenzhen Songjing Investment Partnership (Limited Partnership) guarantees that the information provided to the company is true, accurate, complete, and free from false records, misleading statements, or significant omissions. The company and all members of the board of directors guarantee that the announcement content is consistent with the information disclosed by the information disclosure obligor.
I. Basic Information of the Share Increase Plan
Baolingbao Bio-Technology Co., Ltd. (hereinafter referred to as "the Company" or "Baolingbao") announced that Mr. Dai Sicong, one of the actual controllers, controls Shenzhen Songjing Investment Partnership (Limited Partnership) (hereinafter referred to as "Songjing Investment"). The original plan was to increase the company's shares within six months starting from October 8, 2024, through methods permitted by the Shenzhen Stock Exchange system (including but not limited to centralized bidding and block trading), intending to acquire no less than 18,488,369 shares (5% of the total share capital at that time) and no more than 36,976,738 shares (10% of the total share capital at that time). The share increase does not set a fixed price or price range; the aforementioned increasing entity will implement the plan based on the company's stock price fluctuations and the overall trend of the capital market. For specific details, please refer to the announcement titled "Announcement on the Share Increase Plan by Enterprises Controlled by Actual Controller" disclosed by the company on October 8, 2024, in designated information disclosure media.
On March 21, 2025, the company held the seventh meeting of the sixth board of directors and the fourth meeting of the sixth supervisory board, which approved the proposal to postpone the implementation of the share increase plan, agreeing to extend the original completion date from April 7, 2025, to April 7, 2026, while other contents of the original plan remain unchanged. For specific details, please refer to the announcement titled "Announcement on the Postponement of the Share Increase Plan by Enterprises Controlled by Actual Controller" disclosed by the company on March 22, 2025, in designated information disclosure media.
On April 7, 2025, the company held its first extraordinary general meeting of shareholders in 2025, which approved the aforementioned matters. The implementation period of this share increase plan was changed from "October 8, 2024, to April 7, 2025" to "October 8, 2024, to April 7, 2026." Mr. Dai Sicong, the actual controller of Songjing Investment, is a permanent resident of Hong Kong. To better fulfill the above share increase commitment and in conjunction with Mr. Dai's overseas fund allocation arrangements, a new overseas entity, CEDARWALK BIOTECH HONG KONG LIMITED, was added as one of the implementing entities of this share increase plan. CEDARWALK BIOTECH HONG KONG LIMITED opened an RQFII one-to-one special account product at Guotou Securities Asset Management (Hong Kong) Co., Ltd., named Guotou Securities International Financial Holdings Co., Ltd. - Investment Plan No. 2 (hereinafter referred to as "Investment Plan No. 2"), to implement this share increase plan. Other contents of the original plan remain unchanged. For specific details, please refer to the announcement titled "Announcement on the Increase of Implementing Entities and the Share Increase Plan Reaching 1% Threshold" disclosed by the company on February 6, 2026, in designated information disclosure media.
As of February 5, 2026, Songjing Investment and Investment Plan No. 2 had collectively increased their holdings in the company by 10,196,400 shares, accounting for 2.68% of the total share capital of the company. For specific details, please refer to the announcement titled "Notice on the Share Increase Reaching 1% Threshold and Changes in Shareholder Equity" and the "Detailed Report on Changes in Equity" disclosed by the company on February 7, 2026, in designated information disclosure media.